The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Arotinolol     5-[2-[2-hydroxy-3-(tert...

Synonyms: Arotinololum, CHEMBL93298, SureCN80713, NSC-317940, S-596, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Arotinolol

 

High impact information on Arotinolol

 

Chemical compound and disease context of Arotinolol

 

Biological context of Arotinolol

 

Anatomical context of Arotinolol

 

Associations of Arotinolol with other chemical compounds

 

Gene context of Arotinolol

 

Analytical, diagnostic and therapeutic context of Arotinolol

  • A placebo-controlled, double-blind crossover study was undertaken in 10 normal subjects to examine the effects of arotinolol (10 mg bid), a nonselective beta blocker with alpha-blocking activity, on exercise capacity and hormone levels during exercise after a 2-week treatment period [26].
  • A method for the simultaneous determination of +S and -R arotinolol in serum by micellar electrokinetic capillary chromatography is described [9].
  • Enantioselective determination of arotinolol in human plasma by HPLC using teicoplanin chiral stationary phase [28].
  • To compare the effects of an alpha, beta blocker, arotinolol, in the treatment of essential hypertension between patients with a dipper and those with a non-dipper profile by means of 24-h ambulatory blood pressure monitoring (ABPM), a multicenter single blind parallel trial was carried out in five clinical centers [29].

References

  1. Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. Watanabe, H., Kakihana, M., Ohtsuka, S., Sugishita, Y. J. Am. Coll. Cardiol. (1998) [Pubmed]
  2. Treatment of essential tremor with arotinolol. Kuroda, Y., Kakigi, R., Shibasaki, H. Neurology (1988) [Pubmed]
  3. Effects of long-term therapy with arotinolol on blood pressure and renal function in hypertensive patients with chronic renal failure. Shiigai, T. Clinical therapeutics. (1993) [Pubmed]
  4. The alpha/beta-adrenergic receptor blocker arotinolol activates the thermogenesis of brown adipose tissue in monosodium-L-glutamate-induced obese mice. Yoshida, T., Sakane, N., Wakabayashi, Y., Yoshioka, K., Umekawa, T., Kondo, M. Int. J. Obes. Relat. Metab. Disord. (1994) [Pubmed]
  5. Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys. Kuno, S., Mizuta, E., Nishida, J., Takechi, M. Clinical neuropharmacology. (1992) [Pubmed]
  6. Adrenergic receptor effects and antihypertensive actions of beta-adrenoceptor-blocking agents with ancillary properties. Imai, S., Nakahara, H., Nakazawa, M., Takeda, K. Drugs (1988) [Pubmed]
  7. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. Kurosaki, K., Ikeda, U., Maeda, Y., Shimada, K. J. Mol. Cell. Cardiol. (2000) [Pubmed]
  8. Effects of arotinolol on serum lipid and apolipoprotein levels in patients with mild essential hypertension. Sasaki, J., Handa, K., Arakawa, K. Clinical therapeutics. (1989) [Pubmed]
  9. Micellar electrokinetic capillary chromatography determination of +S and -R arotinolol in serum using UV detection and solid phase extraction. Hefnawy, M.M. Chirality. (2002) [Pubmed]
  10. Comparative effects of arotinolol, labetalol and propranolol on regional myocardial dysfunction induced by flow-limiting coronary stenosis in anesthetized dogs. Noguchi, K., Kato, T., Kinjo, N., Moromizato, H., Sakanashi, M. Jpn. J. Pharmacol. (1990) [Pubmed]
  11. Nifedipine and arotinolol in combination for accelerated-malignant hypertension: results of one year follow-up. Nakamoto, H., Nemoto, H., Sugahara, S., Okada, H., Suzuki, H. Hypertens. Res. (1999) [Pubmed]
  12. Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers. Imai, Y., Watanabe, N., Hashimoto, J., Nishiyama, A., Sakuma, H., Sekino, H., Omata, K., Abe, K. Eur. J. Clin. Pharmacol. (1995) [Pubmed]
  13. Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs. Liu, Q., Nakae, I., Takahashi, M., Takaoka, A., Kinoshita, M. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1996) [Pubmed]
  14. Effect of ophthalmic administration of S-596 (Arotinolol) on intraocular pressure and haemodynamics in health volunteers: comparison with timolol. Nakashima, M., Uematsu, T., Takiguchi, Y., Hashimoto, H., Watanabe, I., Morioka, S., Hibino, T. Eur. J. Clin. Pharmacol. (1985) [Pubmed]
  15. Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes. Zhao, J., Golozoubova, V., Cannon, B., Nedergaard, J. Can. J. Physiol. Pharmacol. (2001) [Pubmed]
  16. Beta-3 adrenergic agonist, BRL-26830A, and alpha/beta blocker, arotinolol, markedly increase regional blood flow in the brown adipose tissue in anesthetized rats. Takahashi, H., Yoshida, T., Nishimura, M., Nakanishi, T., Kondo, M., Yoshimura, M. Jpn. Circ. J. (1992) [Pubmed]
  17. Effects of arotinolol on hemodynamics and adrenergically induced renin release and renal vasoconstriction. Suzuki-Kusaba, M., Hisa, H., Kimura, T., Satoh, S. Arzneimittel-Forschung. (1988) [Pubmed]
  18. Possible alpha-adrenoceptor blocking activity of arotinolol (S-596), a new beta-adrenoceptor blocking agent in isolated dog coronary artery. Sakanashi, M., Miyamoto, Y., Ito, H., Takeo, S., Noguchi, K., Higa, T. Pharmacology (1984) [Pubmed]
  19. Influence of long-term arotinolol treatment on myocardial mechanics and ventricular myosin isoenzymes in spontaneously hypertensive rats. Takeda, N., Ohkubo, T., Iwai, T., Tanamura, A., Nagano, M. Archives internationales de pharmacodynamie et de thérapie. (1990) [Pubmed]
  20. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Morita, S., Miwa, H., Kondo, T. Parkinsonism Relat. Disord. (2005) [Pubmed]
  21. Mechanism of the hypotensive effect of a new beta-adrenergic blocking drug, arotinolol (S-596) in anesthetized rabbits. Nakahara, H., Nakazawa, M., Tsukada, T., Imai, S. Archives internationales de pharmacodynamie et de thérapie. (1985) [Pubmed]
  22. Control of blood pressure and prevention of end-organ damage in patients with accelerated hypertension by combination with arotinolol and extended release nifedipine. Suzuki, H., Nakamoto, H., Nemoto, H., Sugahara, S., Okada, H. Hypertens. Res. (2000) [Pubmed]
  23. Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats. Inagaki, O., Sudoh, K., Shibasaki, M., Nakagawa, C., Honda, K. J. Cardiovasc. Pharmacol. (1994) [Pubmed]
  24. Effects of beta-adrenergic blockers on drug-induced tremors. Iwata, S., Nomoto, M., Fukuda, T. Pharmacol. Biochem. Behav. (1993) [Pubmed]
  25. Effects of arotinolol, an alpha- and beta-adrenoceptor antagonist, on renin release from rat kidney cortical slices. Morimoto, S., Miyawaki, N., Sasaki, Y., Matsumura, Y. Clin. Exp. Pharmacol. Physiol. (1986) [Pubmed]
  26. Effects of arotinolol on exercise capacity and humoral factors during exercise in normal subjects. Mori, T., Handa, K., Terao, Y., Tanaka, H., Kiyonaga, A., Shindo, M., Matsunaga, A., Sasaki, J., Arakawa, K. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1992) [Pubmed]
  27. Effect of arotinolol on hemodynamics and plasma atrial natriuretic peptide at rest and during stress in spontaneously hypertensive rats. Yamamoto, J., Matsubara, H., Nakai, M. Clinical and experimental hypertension. Part A, Theory and practice. (1989) [Pubmed]
  28. Enantioselective determination of arotinolol in human plasma by HPLC using teicoplanin chiral stationary phase. Aboul-Enein, H.Y., Hefnawy, M.M. Biomed. Chromatogr. (2003) [Pubmed]
  29. Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. Wu, H., Zhang, Y., Huang, J., Zhang, Y., Liu, G., Sun, N., Yu, Z., Zhou, Y. Hypertens. Res. (2001) [Pubmed]
 
WikiGenes - Universities